Abstract | BACKGROUND: Mycobacterium xenopi is a common agent of non-tuberculous mycobacterial lung diseases in Europe. However, an optimal treatment regimen for M. xenopi infection has not yet been established. Appropriate in vitro and in vivo model systems are needed for characterization of the activity of potential drugs and drug combinations against M. xenopi. METHODS: We utilized three experimental platforms to analyse the anti-M. xenopi activity of single and combination drug regimens. First, we determined the bacteriostatic and bactericidal activities of drugs alone and in combination in vitro. Second, we used serum from treated mice to evaluate drug activities ex vivo. Third, we analysed M. xenopi growth in four strains of mice (BALB/c, C57BL/6, beige and athymic nude) and developed a mouse model of chemotherapy for this infection. RESULTS: CONCLUSION:
|
Authors | Claire Andréjak, Deepak V Almeida, Sandeep Tyagi, Paul J Converse, Nicole C Ammerman, Jacques H Grosset |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 68
Issue 3
Pg. 659-65
(Mar 2013)
ISSN: 1460-2091 [Electronic] England |
PMID | 23129730
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
|
Topics |
- Animals
- Antitubercular Agents
(administration & dosage)
- Disease Models, Animal
- Drug Therapy, Combination
(methods)
- Female
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Nude
- Mycobacterium Infections, Nontuberculous
(drug therapy)
- Mycobacterium xenopi
(drug effects)
- Treatment Outcome
|